Question · Q2 2024
Asked about the competitive landscape in light of failures in the BTK inhibitor class and the potential for vidofludimus to leapfrog them. Also inquired about the next steps for a Phase III trial following a positive CALLIPER readout, including the target population.
Answer
The recent disappointments in the BTK inhibitor class have opened doors and created an opportunity for vidofludimus as a differentiated alternative. The company is already planning a single Phase III trial for progressive MS, which would likely focus on the non-relapsing secondary progressive population due to the high unmet need, contingent on the strength of the CALLIPER data and overall partnership strategy.